Ranolazine lowers the levels of glycated hemoglobin and fasting blood glucose, and it inhibits the release of glucagon in diabetic patients, which has a positive effect on the treatment of diabetes (Chisholm et al., 2010; Dhalla et al., 2014; Eckel et al., 2015). Here, GCG is linked to diabetes mellitus.